ESC Premium Access

Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab

Congress Presentation

About the speakers

Doctor Enrique Canedo Guerra

Tlalpan (Mexico)
1 follower

Doctor Nilda Espinola-Zavaleta

National Institute of Cardiology Ignacio Chavez, Mexico City (Mexico)
2 presentations
0 follower

5 more presentations in this session

Prospective screening and proposed treatment algorithm for immune checkpoint inhibitor induced myositis in neoadjuvant-treated rectal cancer patients: data from the phase II CHINOREC trial

Speaker: Doctor R. Zirnbauer (Vienna, AT)

Thumbnail

Cardioprotective role of statins in breast cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis

Speaker: Doctor S. Lingamsetty (Khammam, IN)

Thumbnail

Anthracycline-induced arterial toxicity: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography

Speaker: Doctor S. Rankin (Glasgow, GB)

Thumbnail

Comparison of two anthracycline regimens for treatment of breast cancer and the incidence of cardiac injury

Speaker: Doctor N. Osataphan (Chiang Mai, TH)

Thumbnail

Incidence, definitions and outcomes of anthracycline induced subclinical and clinical left ventricular dysfunction: a systematic review and meta-analysis

Speaker: Doctor N. Farooqui (Rochester, US)

Thumbnail

Access the full session

Cardiomyopathy in cancer patients: prevalence, risk assessment, imaging, and prevention

Speakers: Doctor E. Guerra, Doctor N. Espinola-Zavaleta, Doctor R. Zirnbauer, Doctor S. Lingamsetty, Doctor S. Rankin...
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations